SOUTHAMPTON, United Kingdom,
Jan. 6, 2022 /PRNewswire/
-- Synairgen plc (LSE: SNG), the respiratory company
developing SNG001 (inhaled interferon-beta or IFN-beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs, today announces a partnership with global experts in
strategic engagement and commercialisation, Ashfield Engage.
Leveraging its COVID-19 experience, Ashfield Engage is
supporting Synairgen as it builds its commercialisation
infrastructure for the needs of SNG001, initially in the US,
pending completion of pivotal trials and regulatory authorisations.
This will include the recruitment of dedicated medical affairs,
patient services, commercial and market access teams.
SNG001 is an investigational inhaled formulation of the
naturally occurring antiviral protein IFN-beta for potential use in
patients hospitalised with COVID-19. The SARS-CoV-2 virus
supresses local production of IFN-beta prevents induction of
anti-viral responses by infected cells.
"There remains an urgent need for new therapies to treat
hospitalised COVID-19 patients in order to prevent disease
progression, accelerate hospital discharge and enable patients to
quickly resume their usual activities," said Richard Hennings, Chief Commercial Officer of
Synairgen. "We are excited to be working with Ashfield Engage
given their relevant COVID-19 experience and are confident they
understand our needs and values as we build the optimal team."
In November 2021, Synairgen
announced that it had completed enrolment of 610 patients in its
Phase 3 SPRINTER trial (SG018) and expects top-line data early this
year. SNG001 has also recently graduated to the Phase 3 part of the
US National Institute of Health's ACTIV-2 trial.
Greg Flynn, Global President
of Ashfield Engage, said: "It is a privilege to support
Synairgen in bringing this innovative potential treatment to
COVID-19 patients. Having initially collaborated with Synairgen
regarding patient support, we have together developed a truly
consultative approach – taking the time to fully understand patient
needs and providing solutions in both hospital and home
settings.
"We're grateful that our collaboration has now evolved into a
significantly wider partnership which will see us recruiting
experts to support delivery of this novel nebulised antiviral to
patients, providing MSLs to educate on the SNG001 treatment, and
establishing medical information services to respond to patient
enquiries."
SNG001 has been granted Fast Track status from the US Food and
Drug Administration (FDA) and the Phase 3 SPRINTER trial was
classified as an Urgent Public Health study by the UK's National
Institute for Health Research (NIHR).
No financial terms have been disclosed regarding the partnership
with Ashfield Engage.
For further enquiries, please contact:
Synairgen plc
Richard
Marsden, Chief Executive Officer
John Ward, Chief Financial
Officer
Brooke Clarke, Head of
Communications
Brooke.Clarke@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate
Bannatyne, Charlie Beeson
(Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie
Barnfield, Duncan
Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and
Investor Relations)
Mary-Jane
Elliott, Jessica Hodgson,
Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory
company focused on drug discovery, development and
commercialisation. The Company's primary focus is developing SNG001
(inhaled interferon beta) for the treatment of COVID-19 as
potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. SNG001 has been
granted Fast Track status from the US Food and Drug Administration
(FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public
Health study by the UK's National Institute for Health Research
(NIHR). Synairgen's Phase 3 clinical programme is currently
evaluating SNG001 in patients across 17 countries. In a Phase 2
trial in hospitalised COVID-19 patients, SNG001 demonstrated a
greater than two-fold chance of recovery to 'no limitation of
activities' versus placebo.1
Founded by University of Southampton Professors Sir Stephen Holgate, Donna
Davies and Ratko Djukanovic
in 2003, Synairgen is quoted on AIM (LSE: SNG). For more
information about Synairgen, please see www.synairgen.com.
1https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
About Ashfield Engage
Ashfield Engage is an expert, global partner in customer
strategy and execution. Ashfield Engage helps clients to connect
with all healthcare audiences to ensure people get knowledge,
support and medicines when and where they need them. As experts in
strategic engagement, Ashfield Engage creates personalised,
impactful experiences for all healthcare audiences, across all
channels. Every programme is underpinned by human connections,
omnichannel engagement and adaptive analytics.
Ashfield Engage has over 20 years' experience with a team of
over 5,000 employees, delivering services in more than 50
countries. Offering services across Medical Affairs, Commercial,
Patient Solutions and Event Experiences, Ashfield Engage helps its
clients to engage with their stakeholders across the whole
commercialisation journey.
For more information, visit www.ashfieldengage.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/synairgen-announces-global-strategic-partnership-with-ashfield-engage-301455438.html
SOURCE Synairgen PLC